Radioiodine Therapy

Adjunctive radioactive iodine (131-I) is employed in the postoperative management of patients with well differentiated epithelial thyroid cancers. Ablation of remnant thyroid tissue improves the accuracy of serum thyroglobulin monitoring in follow-up, and in patients presenting with advanced disease, reduces recurrence and mortality. 131-I is also useful in treatment of iodine-avid metastatic thyroid cancer.